XXXX : smooth muscle synchronizer for the management of gastro-intestinal conditions. II. A @entity44407 -controlled, double-blind, crossover clinical evaluation.

@entity1 @entity44407 @entity50573 @entity158
A double-blind, crossover trial was carried out in 40 in- @entity1 with gastro-intestinal spasmodic syndromes to compare the effectiveness and tolerance of @entity50573 and @entity44407 . @entity1 were allocated at random to receive either 100 mg @entity50573 or 150 mg @entity44407 3-times daily for 20 days and were then crossed over, without a wash-out period, to the alternative medication for a further 20 days. After the first dose, @entity158 severity was monitored over 4 hours and changes in intensity compared between groups. During the two 20-day periods, the proportion of @entity1 in complete or almost complete remission was monitored at 10-day intervals, and the pooled data similarly compared. At the end of the 40-day trial period, @entity1 stated their preference for one or other treatment, and the relevant data were processed by sequential analysis. Subjective signs of adverse effects were monitored by questioning every 10 days, and haematology and haematochemistry before and after each phase of the study. The results showed that @entity50573 produced significantly greater @entity158 relief after a single dose in comparison with @entity44407 over the 4 hours of observation. Similarly, it gave significantly more favourable clinical results after both the 10th and 20th day of treatment. Finally, according to the @entity1 ' preference, @entity50573 was significantly preferred (p less than 0.05) in comparison with @entity44407 . Neither treatment was associated with the onset of signs of possible adverse reactions, either subjective or objective.
